Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PFIZ34.SA
Strong BuyPfizer Inc. · Healthcare · United States · $161.7B · Avg Vol: $55K/d
95
StockRankGet insider-trade alerts
Q
58
V
71
M
71
P/E (TTM)
37.2x
ROE
5.0%
D/E
0.7x
Dividend %
4.3%
COMPANY DESCRIPTION
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite.
FINANCIAL SUMMARY (BRL)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 526.7B | 310.0B | 331.2B | 325.7B | -14.8% | 331.6B | 324.0B | 311.5B | -2.2% |
| EPS (BRL) | 1.79 | 0.12 | 0.46 | 0.44 | -37.2% | 0.99 | — | — | — |
| Shares | 22.8B | 22.8B | 22.8B | 22.8B | 0.0% | 22.8B | — | — | — |
| Debt | 181.5B | 368.8B | 331.3B | 332.9B | 22.4% | 330.4B | — | — | — |
| Equity | 498.0B | 463.4B | 459.1B | 450.1B | -3.3% | — | — | — | — |
| Op CF | 152.3B | 45.3B | 66.3B | 60.9B | -26.3% | 69.8B | — | — | — |
| Inv CF | -82.2B | -168.0B | 13.8B | -7.0B | — | — | — | — | — |
| Fin CF | -77.2B | 135.7B | -89.2B | -53.6B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+15.9%
SMA 50SMA 200
Close
$6.95
RSI (14)
66.3
52W High
$7.06
From 52W High
1.0%
SCORE BREAKDOWN
Quality
58
ROIC
4.0%55.7
ROE
5.0%57.5
GP/Assets
22.9%52.1
Op. Margin
27.9%89.1
FCF/Assets
5.3%70.4
Piotroski
497.6
Int. Cover
2.6x46.3
D/E Ratio
0.74x20.6
Current Ratio
1.27x19.1
Value
71
P/E (TTM)
37.2x29.6
EV/EBITDA
6.8x85.3
P/FCF
14.7x72.1
P/B
0.4x98.6
P/S
2.5x62.6
Div Yield
4.3%85.8
Momentum
71
52W High %
98%98.2
RS 6M
12%74.7
SMA 50/200
0.99x56.4
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$161.7B
P/E (Forward)
—
Gross Margin
74.7%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PFIZ34.SA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PFIZ34.SA | Pfizer Inc.(you) | $161.7B | 95 | Strong Buy |
| NVON.MX | Novo Nordisk A/S | $207.3B | 95 | Strong Buy |
| BMY | Bristol-Myers Squibb Company | $137.4B | 99 | Strong Buy |
| SNW.DE | Sanofi | $109.5B | 95 | Strong Buy |
| AMG.DE | Amgen Inc. | $238.5B | 93 | Strong Buy |
| GILD.MX | Gilead Sciences, Inc. | $181.0B | 84 | Strong Buy |
| GSK.L | GSK plc | $100.5B | 87 | Strong Buy |
| MRK.MX | Merck & Co., Inc. | $372.4B | 91 | Strong Buy |
| NOVN.SW | Novartis AG | $299.9B | 86 | Strong Buy |
| ABBV.MX | AbbVie Inc. | $468.4B | 94 | Strong Buy |
Peer medians: ROE 1.9% · P/E 24.0x · Gross margin 52.2%